论文部分内容阅读
目的:探讨乌司他丁对慢性阻塞性肺疾病(COPD)患者血清环氧合酶-2(COX-2)、磷脂酶A2(PLA-2)及肺功能的影响。方法:选取2015年1月至2016年1月我院收治的82例COPD患者,随机分为观察组和对照组。对照组患者采取COPD常规处理,观察组在对照组的基础上给予乌司他丁,检测两组患者治疗前后的COX-2、PLA-2以及肺功能指标FEV1、FVC及FEV1/FVC。结果:治疗前,观察组和对照组的COX-2、PLA-2水平均无统计学差异(P>0.05);治疗后,观察组和对照组的COX-2、PLA-2均比治疗前显著降低,且观察组低于同期对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者各项肺功能指标均无统计学差异(P>0.05);治疗后,观察组的FEV1、FVC及FEV1/FVC均优于对照组(P<0.05)。结论:乌司他丁能够有效降低COPD患者血清COX-2、PLA-2浓度,改善肺功能。
Objective: To investigate the effects of ulinastatin on serum COX-2, PLA-2 and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Methods: From January 2015 to January 2016, 82 COPD patients admitted to our hospital were randomly divided into observation group and control group. The patients in the control group were given routine treatment of COPD. The observation group was given ulinastatin on the basis of the control group. COX-2, PLA-2, FEV1, FVC and FEV1 / FVC were measured before and after treatment in both groups. Results: Before treatment, the levels of COX-2 and PLA-2 in observation group and control group showed no significant difference (P> 0.05). After treatment, COX-2 and PLA-2 in observation group and control group were significantly higher than those before treatment (P <0.05), and the difference between the observation group and the control group was statistically significant (P <0.05). Before treatment, there was no significant difference in the indexes of lung function between the two groups (P> 0.05). After treatment, the FEV1, FVC and FEV1 / FVC in the observation group were better than those in the control group (P <0.05). Conclusion: Ulinastatin can effectively reduce the serum levels of COX-2 and PLA-2 in COPD patients and improve pulmonary function.